Daewoong Pharmaceutical Co., Ltd. Announces Positive Safety Review of Bersiporocin
Daewoong Pharmaceutical announced that its idiopathic pulmonary fibrosis (IPF) drug candidate Bersiporocin received a recommendation to continue its global Phase 2 clinical trial.
- 94 patients enrolled out of 102 planned across Korea and the U.S.
- Third Independent Data Monitoring Committee (IDMC) review confirms safety and continuation of the study.
The IDMC conducted an in-depth evaluation of interim safety data from 89 enrolled patients and found no significant safety concerns that would impact the trial's continuation.
The study is progressing as planned, with approximately 92% of the target population enrolled to date.
Author's summary: Daewoong Pharmaceutical's Bersiporocin passes safety review.
More News
- Meet the Next Generation of Physician Leaders at Rutgers Health
- Deandre Ayton claims Los Angeles Lakers superstars ‘troll him’ to get him going
- Take $200 Off Every M4 MacBook Air, Available From $799
- 2 US Navy aircraft crash in South China Sea
- Extinction rates have slowed across many plant and animal groups, study shows
- CRC Screening Improvements Decrease Mortality, but Disparities Persist
- Liam Hemsworth vs. Gabriella Brooks: Who Has the Higher Net Worth?
- D&H Distributing’s Advanced Solutions Plus Unit To Focus On The Enterprise, ‘A Pivotal Evolution’ For Its Business
- ACCC sues Microsoft over alleged misleading subscription practices in Australia
- The environmental impact of the 2026 World Cup